TISSUE REPAIR LTD (ASX: TRP)
Health care · News and insights
Price unavailable
Latest TRP announcements
Announcement Insights
Tissue Repair Completes 7.2 Million-Share Buy-Back as Wound Trial Advances Toward 2027 FDA Filing
Tissue Repair completed its equal-access buy-back, cancelling 7.2 million shares and leaving approximately 53.3 million on issue after valid tenders fell below the offer limit. Separately, its US Phase III chronic-wound trial had randomised approximately 112 patients by 29 October, with an FDA device application targeted for April 2027 through a pathway the company says could avoid the full recruitment plan; the quarter ended with approximately $5 million in cash.
Updated 06 Nov 2026, 07:55 AM Sydney time
Sources
Becoming a substantial holderNotification of cessation of securities - TRPQuarterly Activities/Appendix 4C Cash Flow ReportUpdate - Notification of buy-back - TRPResults of Buy-backComments
2026-11-02 · Health care
TRP: $0.095 +0.00% · MC: $6M
A notice titled “Becoming a substantial holder” was filed for Tissue Repair Ltd, but the supplied announcement text does not identify the holder or provide details of the holding.
Updated 2026-11-02 16:17
Sources
Becoming a substantial holderComments
2026-10-30 · Health care
TRP: $0.095 +0.00% · MC: $6M
Tissue Repair cancelled 7.2 million shares under its equal-access buy-back, completing the repurchase announced earlier this week. The cancellation leaves approximately 53.3 million ordinary shares on issue.
Updated 2026-10-30 10:22
Sources
Notification of cessation of securities - TRPComments
2026-10-29 · Health care
TRP: $0.095 +5.56% · MC: $6M
Tissue Repair reported approximately 112 patients randomised in its ongoing US Phase III chronic-wound trial and is targeting an FDA device application in April 2027, an alternative pathway it says could avoid the full Phase III recruitment plan. TR Pro+ is now available in all three Australian product formats, while the company ended the quarter with approximately $5 million in cash after receiving an R&D tax refund; underlying operating cash outflows were broadly in line with the prior quarter.
Updated 2026-10-29 12:32
Sources
Quarterly Activities/Appendix 4C Cash Flow ReportComments
2026-10-28 · Health care
TRP: $0.090 +0.00% · MC: $6M
Tissue Repair will buy back all validly tendered shares after applications from eligible shareholders came in below the offer limit, so no scale-back applies. The company expects the buy-back to occur on 29 October, with payment to participating shareholders around 30 October.
Updated 2026-10-28 14:22
Sources
Update - Notification of buy-back - TRPResults of Buy-backComments
Comments